NEW YORK (GenomeWeb) – The GenomeWeb Index rose more than 5 percent in September, outperforming the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, and clawing back the 2 percent drop it saw in August.

All but three of the stocks in the Index — which now tracks 29 firms in the omics research tools and molecular diagnostics space — rose in September, many by double digits. The Dow lost half a percent in September while the Nasdaq rose nearly 2 percent. The Nasdaq Biotech Index rose 3 percent.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.